These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 12393833)

  • 21. [Drug-eluting stents and other anti-restenosis devices].
    Moreno R
    Rev Esp Cardiol; 2005 Jul; 58(7):842-62. PubMed ID: 16022816
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Sirolimus-eluting vs paclitaxel-eluting stents -- the trials confirm differences in clinical outcome].
    Gil RJ
    Kardiol Pol; 2005 Nov; 63(5):574-6; discussion 577. PubMed ID: 16362868
    [No Abstract]   [Full Text] [Related]  

  • 23. Cost analysis from two randomized trials of sirolimus-eluting stents versus paclitaxel-eluting stents in high-risk patients with coronary artery disease.
    Elezi S; Dibra A; Folkerts U; Mehilli J; Heigl S; Schömig A; Kastrati A
    J Am Coll Cardiol; 2006 Jul; 48(2):262-7. PubMed ID: 16843172
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Sirolimus eluting stent fracture following angioplasty of diffuse in-stent restenosis in the right coronary artery.
    Wilczynska J; Rdzanek A; Kochman J; Horszczaruk GJ; Pietrasik A; Opolski G
    Int J Cardiol; 2007 May; 118(1):126-7. PubMed ID: 16908080
    [No Abstract]   [Full Text] [Related]  

  • 25. Drug-eluting stents for secondary prevention of restenosis.
    Kastrati A
    Catheter Cardiovasc Interv; 2004 Nov; 63(3):265-6. PubMed ID: 15505858
    [No Abstract]   [Full Text] [Related]  

  • 26. The Cypher stent: no longer efficacious at three months in the porcine model?
    Lafont A
    Cardiovasc Res; 2004 Sep; 63(4):575-6. PubMed ID: 15306210
    [No Abstract]   [Full Text] [Related]  

  • 27. Restenosis due to underexpansion of sirolimus-eluting stent in a bifurcation lesion.
    Takebayashi H; Kobayashi Y; Dangas G; Fujii K; Mintz GS; Stone GW; Moses JW; Leon MB
    Catheter Cardiovasc Interv; 2003 Dec; 60(4):496-9. PubMed ID: 14624428
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Sirolimus-eluting coronary stents.
    Curfman GD
    N Engl J Med; 2002 Jun; 346(23):1770-1. PubMed ID: 12050335
    [No Abstract]   [Full Text] [Related]  

  • 29. Comparable clinical outcomes with paclitaxel- and sirolimus-eluting stents in unrestricted contemporary practice.
    Cosgrave J; Melzi G; Corbett S; Biondi-Zoccai GG; Agostoni P; Babic R; Airoldi F; Chieffo A; Sangiorgi GM; Montorfano M; Michev I; Carlino M; Colombo A
    J Am Coll Cardiol; 2007 Jun; 49(24):2320-8. PubMed ID: 17572247
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Rapamycin-eluting stents for the treatment of bifurcated coronary lesions: a randomized comparison of a simple versus complex strategy.
    Pan M; de Lezo JS; Medina A; Romero M; Segura J; Pavlovic D; Delgado A; Ojeda S; Melián F; Herrador J; Ureña I; Burgos L
    Am Heart J; 2004 Nov; 148(5):857-64. PubMed ID: 15523318
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cost-effectiveness of sirolimus-eluting stents for treatment of complex coronary stenoses: results from the Sirolimus-Eluting Balloon Expandable Stent in the Treatment of Patients With De Novo Native Coronary Artery Lesions (SIRIUS) trial.
    Cohen DJ; Bakhai A; Shi C; Githiora L; Lavelle T; Berezin RH; Leon MB; Moses JW; Carrozza JP; Zidar JP; Kuntz RE;
    Circulation; 2004 Aug; 110(5):508-14. PubMed ID: 15262844
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cost-effectiveness of the unrestricted use of sirolimus-eluting stents vs. bare metal stents at 1 and 2-year follow-up: results from the RESEARCH Registry.
    Ong AT; Daemen J; van Hout BA; Lemos PA; Bosch JL; van Domburg RT; Serruys PW
    Eur Heart J; 2006 Dec; 27(24):2996-3003. PubMed ID: 17114234
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Efficacy of sirolimus-eluting stents in diabetics with complex coronary lesions].
    Berenguer A; Mainar V; Bordes P; Valencia J; Gómez S
    Rev Esp Cardiol; 2006 Feb; 59(2):117-24. PubMed ID: 16540032
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Sirolimus-eluting stents: safe and effective in the treatment of in-stent restenosis.
    Neumann FJ
    Catheter Cardiovasc Interv; 2005 Oct; 66(2):163-4. PubMed ID: 16158398
    [No Abstract]   [Full Text] [Related]  

  • 35. Incomplete neointimal coverage of sirolimus-eluting stents: angioscopic findings.
    Kotani J; Awata M; Nanto S; Uematsu M; Oshima F; Minamiguchi H; Mintz GS; Nagata S
    J Am Coll Cardiol; 2006 May; 47(10):2108-11. PubMed ID: 16697331
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Rapamycin analogs for stent-based local drug delivery. Everolimus- and tacrolimus-eluting stents.
    Grube E; Buellesfeld L
    Herz; 2004 Mar; 29(2):162-6. PubMed ID: 15054588
    [TBL] [Abstract][Full Text] [Related]  

  • 37. XIENCE V everolimus-eluting coronary stent system: a novel second generation drug-eluting stent.
    Beijk MA; Piek JJ
    Expert Rev Med Devices; 2007 Jan; 4(1):11-21. PubMed ID: 17187467
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparison of sirolimus versus paclitaxel eluting stents for treatment of coronary in-stent restenosis.
    Airoldi F; Briguori C; Iakovou I; Stankovic G; Biondi-Zoccai G; Carlino M; Chieffo A; Montorfano M; Cosgrave J; Michev I; Rogacka R; Sangiorgi GM; Colombo A
    Am J Cardiol; 2006 Apr; 97(8):1182-7. PubMed ID: 16616023
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Drug-delivering coronary artery stents: bare metal threatened by extinction?
    Sigwart U
    Lancet; 2003 Oct; 362(9390):1088. PubMed ID: 14550689
    [No Abstract]   [Full Text] [Related]  

  • 40. [PTCA with drug eluting stent. 90% fewer restenoses in high risk patients].
    MMW Fortschr Med; 2004 Aug; 146(33-34):53. PubMed ID: 15526636
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.